Table 1 Baseline characteristics of included studies
From: The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis
| Â | Â | Â | Sample size | Age | Â | LDH | Â | Â | Â | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First author | Year | Country | Total | Colon | Rectum | Median | Range | Tumor stage | Cutoff | Detection method | Adjuvant chemotherapy | Suvival analysis | Outcome report |
Agrawal | 2013 | USA | 146 | NR | NR | NR | <=50 | IV | 200U/L | serum | NR | Univariate | OS |
Alonso-Espinaco | 2014 | Spanish | 157 | NR | NR | NR | 28–82 | mCRC | NR | serum | FOLFOX/XELOX | Univariate Multivariate | OS PFS |
Asmis | 2011 | Canada | 544 | NR | NR | NR | NR | NR | NR | serum | Cetuximab-based | Univariate Multivariate | OS |
Caputo | 2014 | Italy | 96 | 88 | 6 | NR | 18–80 | T2T3T4/M0 | 248U/L | serum | NO | Univariate | OS PFS |
Cetin | 2012 | Turkey | 168 | NR | NR | NR | NR | mCRC | NR | serum | anti-VEGF therapy | Multivariate | OS |
Chibaudel | 2011 | France | 535 | 349 | 177 | 65 | 29–80 | mCRC | NR | serum | Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy | Univariate Multivariate | OS |
Diouf | 2014 | France | 620 | 398 | 211 | NR | 18–80 | mCRC | NR | serum | FOLFOX4 or FOLFOX7 | Univariate Multivariate | OS |
Formica | 2013 | Italy | 31 | 26 | 5 | 69 | 41–83 | mCRC | 245U/L | serum | FOLFORIN + bevacizumab | Multivariate | PFS |
Galizia | 2008 | Italy | 65 | 53 | 12 | NR | 28–84 | IV with liver metastasis | 450U/L | serum | fluorouracil, folinic and acid, and oxaliplatin/irinotecan | Multivariate | OS |
Giessen | 2013 | German | 215 | 136 | 79 | 61.8 | 32–78 | mCRC/liver metastas | 250U/L | serum | FUFURI or mIROX | Multivariate | OS |
Giessen | 2014 | Italy | 249 | 0 | 249 | 64.6 | 30.6–90.7 | I-III | 171 | serum | Chemotherapy/Radiotherapy/Concomitant chemoradiotherapy | Univariate | OS |
Hannisdal | 1994 | Norway | 100 | 0 | 100 | 69 | 33–87 | Local regional relapse ± metastasis | 500 | serum | chemoradiotherapy | Multivariate | OS |
He | 2013 | China | 239 | 171 | 68 | 57 | 18–83 | mCRC | 245U/L | serum | Folfox/Xelox/Folfiri/Xeliri | Multivariate | OS |
Koukourakis | 2006 | UK | 128 | 78 | 50 | 67 | 41–88 | Dukes B,C,D | NR | IHC | NO | Univariate | OS |
Koukourakis | 2011 | Greece | 179 | NR | NR | NR | 28–83 | mCRC | NR | serum IHC | FOLFOX4 + vatalanib/placebo | Univariate Multivariate | OS |
Lin | 2006 | USA | 66 | NR | NR | 62 | 30–86 | mCRC | 618 | serum | XCEL ± Radiation | Univariate | OS |
Lin | 2005 | China | 45 | 34 | 11 | 32 | 18–39 | Dukes B,C,D | 230 | serum | 5-FU based chemotherapy | Multivariate | OS |
Machida | 2008 | Japan | 103 | 66 | 37 | 62 | 29–80 | mCRC | 300 | serum | LV-modulated 5-FU/irinotecan + 5-FU | Univariate | OS |
Maurel | 2007 | Spain | 120 | NR | NR | 66 | 33–82 | mCRC | 450 | serum | 5-FU + oxaliplatin/irinotecan | Multivariate | OS |
Mekenkam | 2012 | Netherland | 803 | 538 | 260 | 63 | 27–84 | Advanced stage (curative surgery) | NR | serum | capecitabine, irinotecan, oxaliplatin: Sequential VS Combination | Multivariate | OS |